Skip to main content
. 2021 Feb 3;162(4):bqab021. doi: 10.1210/endocr/bqab021

Figure 2.

Figure 2.

FGF19 decreases sEPSC frequency in neurons of the DMV in slices from normoglycemic control mice and increases sEPSC frequency in DMV neurons from hyperglycemic T1DM mice. (A) Voltage clamp recordings of sEPSCs in a DMV neuron from a control mouse and (B) after addition of FGF19 (230 pM). (C) Recording of sEPSCs in a DMV neuron from a T1DM mouse and (D) in FGF19. Lower traces indicated by arrows in (A-D) are expanded from the area indicated with a bar in the top traces in each set; all sEPSC measurements were from neurons voltage-clamped at −85 mV. (E) FGF19 significantly decreased mean sEPSC frequency in control mice (n = 8) and increased mean sEPSC frequency in T1DM mice (n = 7). sEPSC frequency was significantly greater in neurons from T1DM mice than from control mice (*P < 0.05; **P < 0.01; ***P < 0.001). (F) FGF19 did not affect mean sEPSC amplitude in control (n = 8) or T1DM mice (n = 7; P > 0.05). sEPSCs were recorded from control, 2 male and 2 female, and T1DM, 3 male and 2 female mice. In the presence of TTX (2 µM), FGF19 did not affect mean mEPSC frequency (G) or amplitude (H) in control (n = 7; P > 0.05) or T1DM mice (n = 7; P > 0.05). mEPSCs were recorded from control, 2 male and 2 female, and T1DM, 2 male and 2 female mice.